Dudediligence.

MannKind Corporation

MNKDNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$70.1MSep ’24$76.8MDec ’24$78.4MMar ’25$76.5MJun ’25$82.1MSep ’25$112.0MDec ’25$90.2MMar ’26$109.4MJun ’26
Net income, by quarter
$11.6MSep ’24$7.4MDec ’24$13.2MMar ’25$668,000Jun ’25$8.0MSep ’25−$15.9MDec ’25−$16.6MMar ’26−$19.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$75.4M$99.8M$199.0M$285.5M$349.0M
Gross profit$58.6M$83.8M$178.1M$268.1M$322.2M
Operating income−$47.0M−$64.1M$8.7M$72.6M$38.8M
Net income−$80.9M−$87.4M−$11.9M$27.6M$5.9M
Operating cash flow−$61.7M−$80.7M$34.1M$42.5M$18.3M
Free cash flow−$73.2M−$88.3M−$8.3M$32.8M$13.7M
Cash$124.2M$69.8M$238.5M$46.3M$74.9M
Debt$281.2M$273.5M$268.7M$36.1M$354.6M
Shares outstanding251.5M263.8M270.0M303.0M307.8M